BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sgalla G, Comes A, Lerede M, Richeldi L. COVID-related fibrosis: insights into potential drug targets. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34842488 DOI: 10.1080/13543784.2021.2010188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Raschi E, Fusaroli M, Gatti M, Caraceni P, Poluzzi E, De Ponti F. Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal. Pharmaceuticals (Basel) 2022;15:645. [PMID: 35631471 DOI: 10.3390/ph15050645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Li J, Chen G, Meng Z, Wu Z, Gan H, Zhu X, Han P, Liu T, Wang F, Gu R, Dou G. Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection. Molecules 2022;27. [PMID: 35566097 DOI: 10.3390/molecules27092745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gu C, Li W, Ju Q, Yao H, Yang L, An B, Hu W, Li X. Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents. RSC Adv 2022;12:14492-501. [DOI: 10.1039/d2ra00990k] [Reference Citation Analysis]